Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4085 - Impact of the 8th edition AJCC classification in early stage lung cancer

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Alexandra Sabela Cortegoso Mosquera

Citation

Annals of Oncology (2018) 29 (suppl_8): viii483-viii487. 10.1093/annonc/mdy290

Authors

A.S. Cortegoso Mosquera1, M. Vieito Villar2, C. Rodriguez Lopez1, V. Varela Pose1, V. Cebey Lopez1, J. Alvarez Fernandez1, M. Perez Martelo1, S. Aguin Losada1, U. Anido Herranz1, L. Leon Mateos1, F.J. Baron Duarte3, J.J. Garcia Gonzalez1

Author affiliations

  • 1 Medical Oncology, Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, 15706 - Santiago de Compostela/ES
  • 2 Oncology, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES
  • 3 Medical Oncology, Complejo hospitalario universitario A Coruña, A Coruña/ES
More

Resources

Abstract 4085

Background

Lung cancer is the main cause of cancer death worldwide. Even in early stages the cancer-specific survival is poor due to disease relapse. The TNM classification is the strongest prognostic tool. The 8th AJCC edition has changed the cutpoints for stage, leading to a “stage shift” or a “stage decrease”, mainly reflecting changes in the prognostic score attributed to the tumor diameter. We have reviewed a cohort of patients that were treated before the benefit of adjuvant chemotherapy was proved, in order to corroborate which of the two classifications represents better the risk of recurrence.

Methods

Retrospective analysis of a cohort of 182 patients with lung cancer treated with complete resection and no adyuvant chemotherapy, between 1999 and 2006. Evaluation criteria: overall survival.

Results

1. Patient characteristics: median diagnostic age 68 years (39-86), 90% males, 48% current and 42% former smokers, 37% diagnosed of COPD. 2. Tumor characteristics:

- Histology: squamous 57%, adenocarcinoma 36%.

- Grade: 47% moderately differentiated, 33% undifferentiated. - Pathological staging by TNM edition.Table: 1351P

7th edition n (%)8th edition n (%)
IA44 (24)IA15 (2.7)
IA223 (12.6)
IA326 (14.3)
IB69 (38)IB30 (16)
IIA20 (11)IIA27 (15)
IIB49 (26)IIB46 (25)
IIIA0IIIA25 (14)

3. median OS in our cohort of patients = 79 months (IC95% = 58-100) log Rank test p=NS me OS by pathological stage defined by 8th ed. AJCC: IA1 97 m (IC95% 37-158) IA2 108 m (IC95% 54-162) IA3 139 m (IC95% 13-266) IB 71 m (IC95% 45-96) IIA 35 m (IC95% 19-51) IIB 62 m (IC95% 34-90) IIIA 56 m (IC95% 0-141) 4. OS stage I vs II - by 7th edition: 93 vs 66 m, log Rank test, p = 0.016 - by 8th edition: 97 vs 70 m, log Rank test, p = 0.026 5. COPD as an adverse prognostic factor: meOS = 111 vs 55 months, log Rank test, p = 0.002

Conclusions

In our cohort of patients, the 8th edition of AJCC classification identifies better than the previous edition a group of patients with worse prognosis regarding to a higher size of the tumour and shiftening their pathological stage. Due to the small sample, we couldn’t prove a more accurate prognostic information for the new stage I categories in the 8th edition. COPD is confirmed in our serie as an adverse prognostic clinical factor.

Clinical trial identification

Legal entity responsible for the study

IDIS.

Funding

IDIS.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.